Compare SUVEN LIFE with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES ABBOTT INDIA SUVEN LIFESCIENCES/
ABBOTT INDIA
 
P/E (TTM) x 3.5 55.5 6.4% View Chart
P/BV x 0.8 16.5 5.0% View Chart
Dividend Yield % 2.8 0.4 669.1%  

Financials

 SUVEN LIFESCIENCES   ABBOTT INDIA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
ABBOTT INDIA
Mar-19
SUVEN LIFESCIENCES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3388,834 3.8%   
Low Rs1695,458 3.1%   
Sales per share (Unadj.) Rs52.11,731.1 3.0%  
Earnings per share (Unadj.) Rs6.8211.9 3.2%  
Cash flow per share (Unadj.) Rs8.6219.9 3.9%  
Dividends per share (Unadj.) Rs1.5065.00 2.3%  
Dividend yield (eoy) %0.60.9 65.0%  
Book value per share (Unadj.) Rs65.3945.2 6.9%  
Shares outstanding (eoy) m127.2821.25 599.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.94.1 117.8%   
Avg P/E ratio x37.133.7 110.1%  
P/CF ratio (eoy) x29.632.5 91.0%  
Price / Book Value ratio x3.97.6 51.4%  
Dividend payout %22.030.7 71.6%   
Avg Mkt Cap Rs m32,272151,848 21.3%   
No. of employees `0001.13.5 31.0%   
Total wages/salary Rs m6614,356 15.2%   
Avg. sales/employee Rs Th6,132.210,555.5 58.1%   
Avg. wages/employee Rs Th611.11,249.9 48.9%   
Avg. net profit/employee Rs Th803.51,292.2 62.2%   
INCOME DATA
Net Sales Rs m6,63536,786 18.0%  
Other income Rs m2421,133 21.4%   
Total revenues Rs m6,87737,919 18.1%   
Gross profit Rs m1,6046,047 26.5%  
Depreciation Rs m221169 130.9%   
Interest Rs m3823 167.6%   
Profit before tax Rs m1,5876,989 22.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7182,485 28.9%   
Profit after tax Rs m8694,503 19.3%  
Gross profit margin %24.216.4 147.1%  
Effective tax rate %45.235.6 127.2%   
Net profit margin %13.112.2 107.0%  
BALANCE SHEET DATA
Current assets Rs m6,23227,610 22.6%   
Current liabilities Rs m1,4908,569 17.4%   
Net working cap to sales %71.551.8 138.1%  
Current ratio x4.23.2 129.8%  
Inventory Days Days8660 143.5%  
Debtors Days Days8327 301.5%  
Net fixed assets Rs m4,0431,057 382.6%   
Share capital Rs m127213 59.9%   
"Free" reserves Rs m8,18319,873 41.2%   
Net worth Rs m8,31020,086 41.4%   
Long term debt Rs m180-   
Total assets Rs m10,38929,409 35.3%  
Interest coverage x43.1311.6 13.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.61.3 51.1%   
Return on assets %8.715.4 56.7%  
Return on equity %10.522.4 46.7%  
Return on capital %19.534.9 55.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,622369 1,523.7%   
Fx outflow Rs m1,7994,918 36.6%   
Net fx Rs m3,822-4,549 -84.0%   
CASH FLOW
From Operations Rs m3564,991 7.1%  
From Investments Rs m-279-2,570 10.8%  
From Financial Activity Rs m-225-1,428 15.8%  
Net Cashflow Rs m-148993 -14.9%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 7.9 -  
FIIs % 0.0 0.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.1 213.5%  
Shareholders   37,287 18,270 204.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)

Indian stock markets mostly remained in the negative zone during the week except for Wednesday.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Feb 20, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - STERLING BIOTECH COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS